circ-0007707/miR-429/PDGFD Pathway Regulates the Progression of Gastric Cancer by Modulating the Immune-Gene Signature

Figure 5

The value of PDGFD in immune therapy in gastric cancer. (a)–(h) After analyzing in TISIDB, PDGFD was significantly correlated with eight immune biomarkers in immunotherapy. (i) In TISIDB, PDGFD had the most highly expression in TGF-b dominant type of gastric cancer. (j) and (k) PDGFD was found to be the target of the type III receptor tyrosine kinases.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)